Rethymic (Enzyvant Therapeutics Inc.) for Congenital Athymia

This report addresses whether full-text clinical studies, systematic reviews, and clinical practice guidelines and position statements support the use of Rethymic (Enzyvant Therapeutics Inc.) for increased longevity and immune reconstitution in pediatric patients with congenital athymia.